Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)-Reference-Cited by-同舟云学术

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

Published:2018-01 Issue:1 Volume:73 Page:4-8
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Borgmann Hendrik^ORCID,Lallous Nada,Ozistanbullu Deniz,Beraldi Eliana,Paul Naman,Dalal Kush,Fazli Ladan,Haferkamp Axel,Lejeune Pascale^ORCID,Cherkasov Artem,Gleave Martin E.

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level;Karantanos;Eur Urol,2015

2. Sequencing of agents in castration-resistant prostate cancer;Lorente;Lancet Oncol,2015

3. The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics;Barbieri;Eur Urol,2017

4. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies;Moilanen;Sci Rep,2015

5. Pharmacokinetics, antitumor activity, and safety of odm-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study;Massard;Eur Urol,2016

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

2. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308;Oncology Reports;2024-08-07

3. PSMAx-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer;2024-04-26

4. Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR;Mini-Reviews in Medicinal Chemistry;2024-04

5. Developing a Novel Enzalutamide‐Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells;Current Protocols;2024-04